BISPHOSPHONATE INDUCED OSTEONECROSIS OFTHE JAWS

Nguyen Viet Phuong 1 , , Nghiem Thi Hong Nhung
1 Friendship Hospital, Vietnam
* Tác giả liên hệ:

Thông tin bài viết

Thống kê
Lượt tải: 1 Lượt xem: 3
DOI
10.63947/bvtn.v2i7.11
Xuất bản
27-02-2026
Số Tập 2 Số 7 (2026): Multimodal approaches in geriatrics
Chuyên mục
Nghiên cứu gốc
Danh mục
Nghiên cứu khoa học

Tải bài viết

PDF (Tiếng Anh)

Cách trích dẫn

1.
Viet Phuong N, Thi Hong Nhung N. BISPHOSPHONATE INDUCED OSTEONECROSIS OFTHE JAWS. JHA [Internet]. Vietnam; 2026 tháng 2 27 [cited 2026 tháng 2 28];2(7):86–94. https://tcsuckhoelaohoa.vn/bvtn/article/view/180 doi: 10.63947/bvtn.v2i7.11
Đang tải trích dẫn...
Crossref
Scopus
Google Scholar
Europe PMC

Tóm tắt

Bisphosphonate (BP) is a group of drugs used to treat osteoporosis, multiple myeloma, skeletal metastasis cancer. BP’s mechanism of action is to reduce bone resorption by inhibiting the osteoclasts activity. Therefore, the indication of BP is increasingly widespread and becomes the first class of drugs in the treatment of osteoporosis. At Frienship Hospital, over the past five years, we have encountered 12 cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) at various stages. The key message we wish to convey in this report is to kindly encourage close collaboration between internal medicine specialists and oral maxillofacial surgeons during bisphosphonate therapy, in order to minimize the risk of BRONJ complications for patients.

Từ khóa

Bisphosphonate bisphosphonate induced osteonecrosis of the jaws (BIONJ)

Tài liệu tham khảo

  1. McLeod, Niall MH, Peter A. Brennan, and Salvatore L. Ruggiero."Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review." The Surgeon 10.1 (2012): 36-42.
  2. Marx, R.E, and R.Tursun. "Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease." International journal of oral and maxillofacial surgery
  3. 41.3 (2012): 283-289.
  4. Tetsuro Ikebe. Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw. Oral Science International, Volume 10, Issue 1. 2013. Pages 1-8. ISSN 1348-8643.
  5. Huỳnh Anh Lan, Bùi Hữu Lâm. Hoại tử xương hàm liên quan bisphosphonate – Những điều cần biết trong thực hành răng hàm mặt. Thời sự y học, 11/2016.
  6. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. The Journal of clinical investigation, 1996.
  7. Ruggiero L.S, Dodson T.B, Assael L.A. American association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws- 2009 update. J Oral Maxillofac Surg 2009; 67: 2- 12.
  8. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 Sep-Oct;7(5):377-87.
  9. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008 Jan;139(1):23-30.
  10. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S., HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 2007 Nov 01;357(18):1799-809.
  11. Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig. 2013 Feb;33(2):117-22.
  12. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J. Oral Maxillofac. Surg. 2007 Jul;65(7):1328-31.
  13. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 2005 Nov;63(11):1567-75.
  14. Mellal A, Wiskott HW, Botsis J, Scherrer SS, Belser UC. Stimulating effect of implant loading on surrounding bone. Comparison of three numerical models and validation by in vivo data. Clin Oral Implants Res. 2004 Apr;15(2):239-48
  15. Ruggiero L.S., Fantasia J., Carlson E. Bisphophonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Radiol Endod 2006; 102(4):433-441.
  16. Wilde, Frank, et al. "The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw."Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 111.2 (2011): 153-163.
  17. Sandeep Kalraa and Veena Jainb, Dental complications and management of patients on bisphosphonate therapy: A review article. Journal of Oral Biology and Craniofacial Research. 2013 Jan-Apr; 3(1): 25–30.

Giấy phép

© 2026 Tác giả. Xuất bản bởi Tạp chí Sức khỏe và Lão hóa.

Creative Commons License

Tác phẩm này được cấp phép theo Giấy phép Creative Commons Ghi công-Phi thương mại-Không phái sinh 4.0 Quốc tế.